MYGN
Price
$6.48
Change
-$0.07 (-1.07%)
Updated
Dec 26 closing price
Capitalization
604.02M
66 days until earnings call
Intraday BUY SELL Signals
WAT
Price
$386.06
Change
+$1.23 (+0.32%)
Updated
Dec 26 closing price
Capitalization
22.99B
45 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MYGN vs WAT

Header iconMYGN vs WAT Comparison
Open Charts MYGN vs WATBanner chart's image
Myriad Genetics
Price$6.48
Change-$0.07 (-1.07%)
Volume$936.5K
Capitalization604.02M
Waters
Price$386.06
Change+$1.23 (+0.32%)
Volume$231.49K
Capitalization22.99B
MYGN vs WAT Comparison Chart in %
MYGN
Daily Signal:
Gain/Loss:
WAT
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
MYGN vs. WAT commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MYGN is a Buy and WAT is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (MYGN: $6.48 vs. WAT: $386.06)
Brand notoriety: MYGN and WAT are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: MYGN: 84% vs. WAT: 38%
Market capitalization -- MYGN: $604.02M vs. WAT: $22.99B
MYGN [@Medical Specialties] is valued at $604.02M. WAT’s [@Medical Specialties] market capitalization is $22.99B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $12.47B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MYGN’s FA Score shows that 1 FA rating(s) are green whileWAT’s FA Score has 1 green FA rating(s).

  • MYGN’s FA Score: 1 green, 4 red.
  • WAT’s FA Score: 1 green, 4 red.
According to our system of comparison, WAT is a better buy in the long-term than MYGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MYGN’s TA Score shows that 2 TA indicator(s) are bullish while WAT’s TA Score has 5 bullish TA indicator(s).

  • MYGN’s TA Score: 2 bullish, 4 bearish.
  • WAT’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, WAT is a better buy in the short-term than MYGN.

Price Growth

MYGN (@Medical Specialties) experienced а -1.07% price change this week, while WAT (@Medical Specialties) price change was +2.12% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.78%. For the same industry, the average monthly price growth was -3.19%, and the average quarterly price growth was +22.19%.

Reported Earning Dates

MYGN is expected to report earnings on Mar 03, 2026.

WAT is expected to report earnings on Feb 10, 2026.

Industries' Descriptions

@Medical Specialties (+0.78% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
WAT($23B) has a higher market cap than MYGN($604M). WAT YTD gains are higher at: 4.065 vs. MYGN (-52.735). WAT has higher annual earnings (EBITDA): 1.04B vs. MYGN (-362.6M). WAT has more cash in the bank: 459M vs. MYGN (145M). MYGN has less debt than WAT: MYGN (212M) vs WAT (1.49B). WAT has higher revenues than MYGN: WAT (3.11B) vs MYGN (825M).
MYGNWATMYGN / WAT
Capitalization604M23B3%
EBITDA-362.6M1.04B-35%
Gain YTD-52.7354.065-1,297%
P/E RatioN/A35.48-
Revenue825M3.11B27%
Total Cash145M459M32%
Total Debt212M1.49B14%
FUNDAMENTALS RATINGS
MYGN vs WAT: Fundamental Ratings
MYGN
WAT
OUTLOOK RATING
1..100
5257
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
10052
SMR RATING
1..100
9828
PRICE GROWTH RATING
1..100
6447
P/E GROWTH RATING
1..100
250
SEASONALITY SCORE
1..100
n/a8

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

WAT's Valuation (88) in the Medical Specialties industry is in the same range as MYGN (99) in the Biotechnology industry. This means that WAT’s stock grew similarly to MYGN’s over the last 12 months.

WAT's Profit vs Risk Rating (52) in the Medical Specialties industry is somewhat better than the same rating for MYGN (100) in the Biotechnology industry. This means that WAT’s stock grew somewhat faster than MYGN’s over the last 12 months.

WAT's SMR Rating (28) in the Medical Specialties industry is significantly better than the same rating for MYGN (98) in the Biotechnology industry. This means that WAT’s stock grew significantly faster than MYGN’s over the last 12 months.

WAT's Price Growth Rating (47) in the Medical Specialties industry is in the same range as MYGN (64) in the Biotechnology industry. This means that WAT’s stock grew similarly to MYGN’s over the last 12 months.

MYGN's P/E Growth Rating (2) in the Biotechnology industry is somewhat better than the same rating for WAT (50) in the Medical Specialties industry. This means that MYGN’s stock grew somewhat faster than WAT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MYGNWAT
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
66%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
65%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
57%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
67%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
63%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
66%
Declines
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 10 days ago
60%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
MYGN
Daily Signal:
Gain/Loss:
WAT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ISHP39.07N/A
N/A
First Trust S-Network Glb E-Com ETF
SMTH26.10N/A
N/A
ALPS Smith Core Plus Bond ETF
USMF51.92-0.15
-0.29%
WisdomTree US Multifactor
AFGE16.88-0.09
-0.53%
American Financial Group
BIB82.74-1.12
-1.34%
ProShares Ultra Nasdaq Biotechnology

MYGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with WAT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then WAT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYGN
1D Price
Change %
MYGN100%
-1.07%
WAT - MYGN
39%
Loosely correlated
+0.32%
ATEC - MYGN
34%
Loosely correlated
+0.94%
AORT - MYGN
31%
Poorly correlated
-1.24%
MASI - MYGN
30%
Poorly correlated
-0.39%
MXCT - MYGN
28%
Poorly correlated
+0.62%
More

WAT and

Correlation & Price change

A.I.dvisor indicates that over the last year, WAT has been closely correlated with A. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if WAT jumps, then A could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WAT
1D Price
Change %
WAT100%
+0.32%
A - WAT
82%
Closely correlated
+0.05%
MTD - WAT
75%
Closely correlated
+0.21%
TMO - WAT
71%
Closely correlated
+0.28%
DHR - WAT
70%
Closely correlated
-0.50%
RVTY - WAT
70%
Closely correlated
-0.03%
More